BRAF V600E NSCLC Clinical Trial Landscape

Key trials in BRAF V600E NSCLC

The table below reflects recruiting and active trials registered on ClinicalTrials.gov targeting BRAF V600E non-small cell lung cancer as of early 2026. DataLookout monitors for new registrations and status changes daily.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting and active trials as of early 2026.

BRAF V600E in NSCLC: a druggable oncogene with an established standard of care

BRAF V600E is one of the clearest examples of successful oncogene translation across tumor types. The combination of dabrafenib (BRAF V600 inhibitor) and trametinib (MEK1/2 inhibitor) was first approved in BRAF V600E-mutant melanoma in 2014, then extended to NSCLC in 2017 based on Phase 2 data demonstrating meaningful activity. This made BRAF V600E-mutant NSCLC only the second solid tumor indication for the doublet and established it as one of the earlier targeted therapies approved specifically in lung cancer.

BRAF V600E accounts for approximately 1–2% of all NSCLC cases — roughly 5,000–8,000 new patients per year in the United States. Despite this rarity, the indication has commercial significance because BRAF V600E testing is now a mandatory component of comprehensive molecular profiling in advanced NSCLC, and because the patient population is well-characterized through clinical trial registration. Unlike some rare NSCLC subgroups, BRAF V600E is not concentrated in any single demographic but does appear slightly more frequently in women and in patients with lighter smoking histories.

BRF113928: the trial that established the standard of care

The approval of dabrafenib + trametinib in NSCLC was based on the BRF113928 Phase 2 trial (NCT01336634), a multi-cohort study enrolling patients with advanced BRAF V600E-mutant NSCLC. The study enrolled three cohorts: Cohort A (dabrafenib monotherapy, previously treated), Cohort B (dabrafenib + trametinib, previously treated), and Cohort C (dabrafenib + trametinib, treatment-naive).

The pivotal results from Cohorts B and C established the doublet as the standard of care:

• Cohort B (previously treated): ORR 63.2%, median PFS 9.7 months, median OS 18.2 months
• Cohort C (treatment-naive): ORR 64.3%, median PFS 10.8 months, median OS 24.6 months
• Cohort A (dabrafenib monotherapy): ORR 27% — confirming MEK co-inhibition is essential for durable responses

The durability of responses with the doublet versus monotherapy established the mechanistic rationale for BRAF + MEK co-inhibition: blocking BRAF V600E alone leads to compensatory MEK/ERK reactivation via paradoxical CRAF activation, which is suppressed by concurrent MEK inhibition. This combination principle, established first in melanoma, proved directly translatable to NSCLC.

The three classes of BRAF mutations: why classification matters

BRAF mutations in NSCLC are not interchangeable. The three-class framework, originally developed in melanoma and validated in NSCLC, determines therapeutic eligibility:

Class 1: V600E/K/R — the actionable subgroup

Class 1 BRAF mutations are constitutively active as monomers, independent of RAS signaling. They respond to BRAF V600-selective inhibitors (dabrafenib, vemurafenib, encorafenib) in combination with MEK inhibitors. BRAF V600E is the dominant Class 1 mutation in NSCLC (~95% of Class 1 cases). Class 1 V600K and V600R mutations are far rarer in NSCLC than in melanoma but are considered co-eligible for the approved indication.

Class 2: Fusions and kinase-active dimers — not targetable with V600 inhibitors

Class 2 mutations (BRAF fusions, K601E, L597Q/V, G469A) are constitutively active as dimers, RAS-independent. BRAF V600-selective inhibitors paradoxically activate Class 2 dimers by transactivating the non-drug-bound protomer. Administering dabrafenib to a Class 2 BRAF-mutant NSCLC patient can worsen outcomes. Class 2 BRAF-mutant NSCLC has no approved targeted therapy and represents an unmet need — RAF dimer inhibitors and SHP2 inhibitors are being investigated as rational approaches.

Class 3: Kinase-impaired, RAS-dependent — different biology

Class 3 mutations (D594G, D594N, G466V/E) impair BRAF kinase activity, paradoxically leading to increased RAS-GTP loading and CRAF-mediated MAPK signaling. These tumors often have co-occurring RAS mutations and represent yet another distinct biology. MEK inhibitor monotherapy has theoretical rationale but clinical data in this group is limited.

The encorafenib opportunity: BRAF V600E basket trial activity

Encorafenib (Braftovi, Pfizer) is a BRAF V600 inhibitor approved in combination with binimetinib (Mektovi) for BRAF V600E/K-mutant unresectable or metastatic melanoma, and in combination with cetuximab for BRAF V600E-mutant metastatic colorectal cancer (the BEACON-CRC regimen). These approvals generate substantial interest in encorafenib's activity across other BRAF V600E solid tumors, including NSCLC.

Encorafenib has several pharmacological differences from dabrafenib that may be clinically relevant in NSCLC. It has a longer dissociation half-life from BRAF (~30 hours vs. ~2 hours for vemurafenib), which is thought to reduce paradoxical MAPK activation. It also has a different toxicity profile — lower rates of pyrexia compared to dabrafenib + trametinib, which is a common dose-limiting adverse event in the approved regimen. Whether these pharmacological differences translate into meaningfully different efficacy or tolerability in NSCLC is an active question. Basket trial data from NCT04005690 and related studies are generating the early NSCLC evidence base for encorafenib combinations.

Pan-RAF inhibitors: the next frontier in post-progression BRAF V600E NSCLC

A significant unmet need in BRAF V600E NSCLC is the absence of approved second-line targeted options after dabrafenib + trametinib failure. Resistance to BRAF/MEK doublets in NSCLC resembles the melanoma resistance landscape: MAPK pathway reactivation (BRAF amplification, KRAS mutation, MEK1/2 mutations), bypass pathway activation (PI3K/AKT/mTOR, MET amplification), and histologic transformation (squamous differentiation in adenocarcinoma).

Pan-RAF inhibitors — molecules designed to inhibit all RAF family members (ARAF, BRAF, CRAF) as well as RAF dimers — represent a rationally designed approach to overcome resistance. Naporafenib (LXH254, Novartis) is the most advanced pan-RAF inhibitor in clinical development for NSCLC, currently being studied in combination with trametinib (NCT05385822) in BRAF- and KRAS-altered tumors. Unlike BRAF V600-selective inhibitors, pan-RAF inhibitors do not trigger paradoxical MAPK activation in Class 2 BRAF-mutant or RAS-mutant contexts, potentially extending their utility beyond the narrow V600E niche.

Checkpoint immunotherapy and BRAF V600E NSCLC: a complex relationship

BRAF V600E-mutant NSCLC presents a more complex immunotherapy context than BRAF V600E melanoma. In melanoma, the combination of BRAF/MEK inhibition with PD-1 or PD-L1 blockade has shown promising Phase 3 results (IMspire150 with vemurafenib + cobimetinib + atezolizumab), though sequential rather than concurrent combination has been explored to manage overlapping toxicities.

In NSCLC, the picture is less clear. BRAF V600E mutations in lung cancer are not consistently associated with high PD-L1 expression or high tumor mutational burden — two of the main predictors of immunotherapy benefit in unselected NSCLC. Early data from triple combination trials (dabrafenib + trametinib + pembrolizumab, NCT04552210; vemurafenib + cobimetinib + atezolizumab, NCT03915951) are generating the NSCLC-specific immunotherapy evidence base. The theoretical rationale for combining BRAF/MEK inhibition with checkpoint blockade includes T-cell derepression via MEK inhibitor immunomodulation and increased antigen presentation from tumor lysis during targeted therapy. Whether this translates to clinically meaningful benefit in NSCLC over the approved doublet remains an active research question.

BRAF V600E NSCLC and the RAS/MAPK pathway: competitive intelligence context

BRAF V600E NSCLC sits within the broader RAS/MAPK pathway oncology landscape that also includes KRAS-mutant NSCLC. Understanding the pipeline requires understanding the pathway context: KRAS mutations (predominantly G12C in NSCLC) and BRAF V600E mutations both drive constitutive MAPK signaling, but through distinct mechanisms — KRAS mutations are upstream of RAF, while BRAF V600E is a direct effector kinase mutation. This has practical implications for drug development: KRAS G12C inhibitors (sotorasib, adagrasib) do not benefit BRAF V600E patients, and vice versa.

The MEK inhibitor trametinib is the shared downstream target across both KRAS and BRAF-driven MAPK pathway activation, but as a single agent or in combination with KRAS inhibitors, trametinib has shown limited efficacy in KRAS-mutant NSCLC due to feedback reactivation loops not present in BRAF V600E tumors. This pathway biology explains why BRAF V600E (with its constitutive, RAS-independent kinase activity) responded dramatically to BRAF + MEK doublets while KRAS-mutant tumors required direct KRAS G12C covalent inhibitors rather than MEK-centric strategies.

Related clinical trials and monitoring resources

BRAF V600E NSCLC is part of the targeted oncology landscape in lung cancer. DataLookout monitors related areas including:

• NSCLC clinical trials — full non-small cell lung cancer pipeline, all molecular subgroups
• KRAS G12C NSCLC clinical trials — the most common NSCLC oncogenic driver; shares RAS/MAPK pathway context
• EGFR mutant lung cancer clinical trials — largest NSCLC molecular subgroup by volume
• ALK-positive lung cancer clinical trials — kinase-fusion paradigm for targeted therapy
• RET-fusion NSCLC clinical trials — another rare fusion-driven NSCLC subtype
• ROS1-fusion NSCLC clinical trials — 1–2% NSCLC; three approved TKIs

Frequently asked questions